Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: mepolizumab Clear all
Terminated Phase 2 Interventional Results available

Mepolizumab in Episodic Angioedema With Eosinophilia

NCT04128371
View directory record Official record
Conditions
Eosinophilia, Angioedema
Interventions
mepolizumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 29, 2026, 4:05 PM EDT
Completed No phase listed Observational Results available

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

NCT05002621
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Observational
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

NCT01366521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02105948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Newport Beach, California • Rochester, Minnesota • Saint Charles, Missouri + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 29, 2026, 4:05 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis
Interventions
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 29, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

NCT00097370
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
10
States / cities
San Diego, California • Denver, Colorado • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis
Interventions
Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Long Beach, California • Newport Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 29, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

NCT03055195
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Mepolizumab 100 mg, Placebo matching mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
11
States / cities
Fort Smith, Arkansas • Fremont, California • Santa Ana, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

NCT02555371
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Cross-sectional Study for Identification and Description of Severe Asthma Patients

NCT02293265
View directory record Official record
Conditions
Asthma
Interventions
Short Acting Beta Agonist (SABA)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
21
States / cities
Little Rock, Arkansas • Fresno, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children

NCT03292588
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

NCT03306043
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

NCT00358449
View directory record Official record
Conditions
Oesophagitis, Eosinophilic
Interventions
mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

NCT00086658
View directory record Official record
Conditions
Hypereosinophilia, Hypereosinophilic Syndrome
Interventions
mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
San Diego, California • Denver, Colorado • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects

NCT01691859
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 29, 2026, 4:05 PM EDT
Recruiting Phase 4 Interventional

Biologics in Chronic Rhinosinusitis With Nasal Polyposis

NCT06824649
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyps
Interventions
Biologic Agents
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Gainesville, Florida • Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 4:05 PM EDT
Completed Early Phase 1 Interventional Results available

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

NCT03494881
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Nucala
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 29, 2026, 4:05 PM EDT